Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.79 |
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.73 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381767 | 1.00 | TLR8 (0.79) | TLR8TLR7NUDT1 | |
| SCHEMBL1952956 | 0.97 | TLR8 (0.80) | TLR8TLR7NUDT1 | |
| SCHEMBL30954539 | 0.97 | TLR8 (0.80) | TLR8TLR7NUDT1 | |
| SCHEMBL6098914 | 0.94 | TLR8 (0.77) | TLR8TLR7NUDT1 | |
| SCHEMBL20467576 | 0.94 | TLR8 (0.80) | TLR8TLR7NUDT1 | |
| SCHEMBL1616206 | 0.92 | TLR8 (0.84) | TLR8TLR7NUDT1 | |
| SCHEMBL4321155 | 0.91 | TLR8 (0.72) | TLR8TLR7NUDT1 | |
| Hydrochloric Acid SCHEMBL3863644 | 0.91 | TLR8 (0.82) | TLR8TLR7NUDT1 | |
| SCHEMBL3868221 | 0.91 | TLR8 (0.75) | TLR8TLR7NUDT1 | |
| Hydrochloric Acid SCHEMBL6493853 | 0.91 | TLR8 (0.82) | TLR8TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090658-A1 | POLYMER ADJUVANT | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-03-20 | — | — | US | disclosed |
| US-20240216497-A1 | Ferritin Proteins | SANOFI (FR) | 2024-07-04 | — | — | US | disclosed |
| US-20240216497-A1 | Ferritin Proteins | SANOFI (FR) | 2024-07-04 | — | — | US | disclosed |
| US-20240173390-A1 | PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | THE U.S.A, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-05-30 | — | — | US | disclosed |
| US-11938177-B2 | Peptide vaccine formulations and use thereof for inducing an immune response | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-03-26 | — | — | US | disclosed |
| US-11904009-B2 | Ferritin proteins | SANOFI (FR) | 2024-02-20 | — | — | US | disclosed |
| US-11904009-B2 | Ferritin proteins | SANOFI (FR) | 2024-02-20 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20120189646-A1 | NOVEL COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| US-20120189646-A1 | NOVEL COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| US-20120189646-A1 | NOVEL COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| WO-2012080728-A1 | IMIDAZO [4, 5 -C] QUINOLIN- 1 -YL DERIVATIVE USEFUL IN THERAPY | ASTRAZENECA AB (SE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080728-A1 | IMIDAZO [4, 5 -C] QUINOLIN- 1 -YL DERIVATIVE USEFUL IN THERAPY | ASTRAZENECA AB (SE) | 2012-06-21 | — | — | WO | disclosed |
| US-8178677-B2 | Hydroxyalkyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-6069149-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | TERUMO KABUSHIKI KAISHA (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0894797-A1 | NOVEL AMIDE DERIVATIVES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF | TERUMO KABUSHIKI KAISHA (JP) | 1999-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173390-A1 | PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | NGLY1, MYD88, SPPL2B | TLR8 52/4885TLR7 69/4885NUDT1 4493/4885 |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | TLR8 494/4885TLR7 194/4885NUDT1 302/4885 |
| US-20240216497-A1 | Ferritin Proteins | FTH1, TFRC, SLC40A1 | TLR8 1882/4885TLR7 3530/4885NUDT1 3796/4885 |
| US-11904009-B2 | Ferritin proteins | FTH1, TFRC, SLC40A1 | TLR8 1882/4885TLR7 3530/4885NUDT1 3796/4885 |
| US-20250090658-A1 | POLYMER ADJUVANT | TLR3, TLR9, TLR1 | TLR8 8/4885TLR7 7/4885NUDT1 3583/4885 |
| US-11938177-B2 | Peptide vaccine formulations and use thereof for inducing an immune response | NGLY1, MYD88, SPPL2B | TLR8 52/4885TLR7 69/4885NUDT1 4493/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | TLR8 9/4885TLR7 4/4885NUDT1 1996/4885 |
| US-20120189646-A1 | NOVEL COMPOUNDS | UGT1A10, SLC10A1, UGT1A1 | TLR8 4734/4885TLR7 4589/4885NUDT1 2932/4885 |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | IFNG, IRF3, IFNAR1 | TLR8 236/4885TLR7 55/4885NUDT1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.